Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG Injection in Combination with Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer

Trial Profile

A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG Injection in Combination with Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odetiglucan (Primary) ; Carboplatin; Cetuximab; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors HiberCell

Most Recent Events

  • 24 Mar 2017 Results published in the Biothera Media Release
  • 16 Mar 2017 Results published in the Investigational New Drugs
  • 02 Jun 2015 Results of pooled analysis of two phase II trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top